Rigel’s Rezlidhia (olutasidenib) Gets FDA Approval for Relapsed or Refractory AML

Rigel’s Rezlidhia (olutasidenib) Gets FDA Approval for Relapsed or Refractory AML

Submitted by admin on December 7, 2022 - 9:53am
Source: 
Xtalks
News Tags: 
Rigel Pharmaceuticals
Rezlidhia
olutasidenib
FDA
AML
Headline: 
Rigel’s Rezlidhia (olutasidenib) Gets FDA Approval for Relapsed or Refractory AML
snippet: 

Rigel Pharmaceuticals’ isocitrate dehydrogenase-1 mutant (mIDH1) targeting small molecule inhibitor Rezlidhia (olutasidenib) has won US Food and Drug Administration (FDA) approval for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML).

Do Not Allow Advertisers to Use My Personal information